Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00937157 · ClinicalTrials.gov registry record · NA
Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)
A NA study, sponsored by University at Buffalo.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT00937157 is a NA study that has completed, run by University at Buffalo. The registered enrollment target is 12 participants.
The verdict
NCT00937157, a NA study, has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study will: * Explore whether GA decreases inflammation more on the 3T optimized protocol when compared to the 1.5T standard protocol. * Compare whether the decrease in the cumulative number of Gd-enhancing lesions significantly differs between pre-treatment (day 0) and post-treatment (12 months) using 1.5T standard and 3T optimized protocols. * Investigate the correlation between MTR and the cumulative number and volume of Gd enhancing lesions on 1.5T standard and 3T optimized protocols in patients treated with GA. This study suggests that GA may favorably affect early events in lesion formation, in addition to exerting more transient beneficial effects on established areas of inflammation and demyelination, and that this effect may be observed only with the 3T optimized protocol.
Interventions
- DRUG Copaxone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-09 |
| Est. Completion | 2011-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00937157
The ClinicalTrials.gov registry entry for NCT00937157 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Copaxone is the first listed.
NCT00937157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00937157 about?
NCT00937157 is a clinical study titled "Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)". This study will: * Explore whether GA decreases inflammation more on the 3T optimized protocol when compared to the 1.5T standard protocol. * Compare whether the decrease in the cumulative number of Gd-enhancing lesions significantly differs between pre-treatment (day 0) and post-treatment (12 m...
What is the current status of trial NCT00937157?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2007-09. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00937157?
The interventions under investigation include: Copaxone (DRUG).
Who is sponsoring clinical trial NCT00937157?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.